What Adalat GITS treats: Main Uses and Benefits

Adalat GITS (Nifedipine GITS) is commonly used to manage chronic cardiovascular conditions by providing long-term symptomatic support across key therapeutic domains. The medication is commonly used in the sustained therapeutic management of hypertension and helps address symptom clusters associated with angina pectoris, including the recurrent chest discomfort or tightness that stems from inadequate oxygen supply to the heart. It is also relevant in clinical contexts marked by intense, fluctuating vasoconstriction episodes, such as those seen in Raynaud's phenomenon.

The use of this medication provides support in easing the physiological strain on the heart and vasculature, which assists with maintaining functional stability and supports overall general well-being during symptomatic phases.

“The medication is generally considered relevant for situations where sustained therapeutic support helps patients cope more steadily with their symptomatic periods.”

This supportive approach is applied in scenarios where patients experience heightened systemic burden, offering symptomatic relief that contributes to improved comfort during symptomatic periods and assists with managing the intensity of chronic or episodic manifestations.

Quick Fact: Support for Chronic Vascular Pressure
Adalat GITS is relevant for long-term support in managing the persistently high systemic pressure associated with essential hypertension.

Regulatory References

1. MedlinePlus Drug Information

Eligibility Constraints for Adalat GITS

Adalat GITS is generally established for use in adult patients (18 years and older) who do not possess any specified contraindications. Eligibility for this medicine is strictly defined by regulatory documents, which establish several populations for whom use is prohibited or restricted.

Contraindicated Populations (Must Not Use):

• Patients with known hypersensitivity to nifedipine or any related dihydropyridine class medication.
• Patients diagnosed with cardiogenic shock.
• Due to the unique GITS delivery system, use is prohibited in patients with oesophageal or gastrointestinal obstruction, narrowing, or those who have had an ileostomy.
• Pregnancy is a contraindication for use.
• Concomitant use with the drug rifampicin is prohibited.

Populations with Restricted Use:

• Pediatric Use: The medication is not recommended for children and adolescents under 18 years of age because safety and efficacy data have not been fully established.
• Hepatic Impairment: Patients with impaired liver function require careful monitoring.
• Lactation: Use is not recommended while breastfeeding.
• Older Adults: Use is permitted, but geriatric patients may require careful monitoring.

Adalat GITS (nifedipine) interacts with other products primarily through the Cytochrome P450 3A4 (CYP3A4) enzyme system, which is responsible for its metabolism. The co-administration of certain medicines or food products can significantly alter the concentration of nifedipine in the body.

Interacting Medicinal Product Categories:

• CYP3A4 Inducers: Medicines that increase CYP3A4 activity, such as the antibiotic rifampicin and the herbal supplement St. John's Wort, can substantially decrease nifedipine plasma concentrations. The use of rifampicin with Adalat GITS is contraindicated due to the risk of significant reduction in efficacy.
• CYP3A4 Inhibitors: Medicines that decrease CYP3A4 activity, including certain antifungal agents (e.g., ketoconazole, itraconazole), macrolide antibiotics (e.g., erythromycin, clarithromycin), HIV protease inhibitors, and cimetidine, can lead to increased nifedipine exposure. Clinical monitoring is advised during co-administration with these agents.

Specific Product Constraints:

• Grapefruit/Grapefruit Juice is explicitly listed as a product that inhibits CYP3A4 metabolism and must be avoided while taking this medicine.
• Nifedipine may also inhibit the metabolism of other co-administered drugs, such as tacrolimus and digoxin, requiring close monitoring of the plasma levels of those specific medicines.

Selective Calcium Channel Blockade

The drug's core mechanism involves its active ingredient, nifedipine, acting as an inhibitor of voltage-dependent L-type calcium channels (Cav1.2). These channels are located predominantly on the membranes of peripheral and coronary arterial smooth muscle cells. The inhibition of these channels prevents the essential influx of extracellular calcium ions (Ca^2+) into the cell, which is a primary molecular signal for muscle contraction.

Regulation of Vascular Tone and Resistance

By restricting calcium entry, nifedipine interferes with the excitation-contraction coupling pathway within arterial smooth muscle. This interference causes the muscle cells to relax, leading to vasodilation (arterial widening). Physiologically, this results in a reduction of the body’s peripheral vascular resistance. The vasodilation affects coronary arteries, modulating myocardial blood flow.

️ The Osmotic Delivery System (GITS)

The Gastrointestinal Therapeutic System (GITS) functions as an osmotic pump by drawing water from the digestive system. This mechanism pushes the nifedipine out at a constant, near zero-order rate for approximately 24 hours. This sustained, stable release maintains consistent calcium channel blockade throughout the dosing interval.

Official Administration Guidelines (Nifedipine Extended-Release)

This information details the required procedure for using Adalat GITS (nifedipine extended-release) as defined by standardized labeling.

Administration Scope	Official Procedure
Route & Frequency	Must be taken orally once daily (q.d.).
Initial Dosing	Therapy typically starts with a 30 mg or 60 mg tablet once daily for adults.
Maintenance Dose	The dose is individualized and can be gradually increased by a healthcare provider, usually over a period of 7 to 14 days, based on individual needs. The maximum dose is typically 90 mg once daily for many formulations.

Procedural Steps and Constraints

1. Swallow the Tablet Whole: The extended-release tablet must be swallowed whole with water. Do not, under any circumstances, bite, chew, crush, or divide the tablet, as this will destroy its specialized release mechanism and lead to an uncontrolled, rapid release of the medication.
2. Consistent Timing: Take the tablet at approximately the same time every day to maintain steady drug levels in the body.
3. Dietary Restriction: Do not consume grapefruit or grapefruit juice while taking this medicine. This is a mandatory restriction to prevent an increase in the amount of nifedipine absorbed, which could lead to unintended effects.
4. Tablet Shell Residue: It is normal to observe the outer shell of the tablet in the stool. This shell does not dissolve and indicates that the medication has been properly released into the system.

Missed Dose: If a dose is missed, take it as soon as possible, unless it is almost time for the next scheduled dose. If it is nearly time for the next dose, skip the missed one and continue the regular schedule. Do not take a double dose to make up for a forgotten dose.

Research Evidence / Overview of Studies for Adalat GITS

The scientific understanding of Adalat GITS (Nifedipine GITS) is primarily built upon large-scale, long-term Randomized Controlled Trials (RCTs), particularly for its main indication, essential hypertension. These extensive studies evaluated outcomes related to physiological strain and measured how blood pressure levels evolved in the observed adult populations. The research focus included measuring Systolic and Diastolic Blood Pressure (BP) changes, as well as evaluating serious, long-term health outcomes, known as major composite cardiovascular events (such as stroke or heart attack).

---

Evidence for Use in Managing Angina Pectoris

For symptomatic stable angina, the evidence primarily comes from a large, long-term, placebo-controlled clinical trial. The research explored patient-reported outcomes describing perceived discomfort and outcomes describing episodic changes. The studies evaluated the frequency of angina episodes and examined major cardiovascular events, including heart failure and the need for revascularization procedures.

For the overall study population, the finding showed a non-statistically distinct pattern regarding the main outcome when compared to the placebo group. Because most participants were concurrently taking other standard medications, comparative evidence on using Adalat GITS alone for stable angina is limited. Data for certain high-risk groups remain insufficient or uncertain.

---

Research Gaps and Uncertainties

The evidence highlights what is known and what is still uncertain. The largest body of evidence comes from the large-scale, long-term RCTs for hypertension, while evidence for other uses, such as Raynaud's phenomenon, includes fewer large-scale studies. For the latter, research often relies on small-scale, short-term trials where data for the GITS formulation specifically are limited, and primary outcomes are based on patient-reported experiences. Furthermore, limited information is available for children regarding the GITS formulation, and long-term effects are not fully established across all patient subgroups.

Key Studies & References Nifedipine Drug Information - MedlinePlus

Common questions about Adalat GITS (FAQ)

Q: What is the difference between Adalat GITS and a regular nifedipine tablet?

A: Adalat GITS is a modified-release tablet that uses a specialized osmotic pump system. This system is designed to release the active ingredient, nifedipine, slowly and continuously over approximately 24 hours. This controlled and steady release is the main difference from immediate-release nifedipine products, which release the medicine much faster.

Q: Can Adalat GITS be used for blood pressure and angina at the same time?

A: Official drug information indicates that nifedipine is approved for the long-term management of both essential hypertension (high blood pressure) and chronic stable angina (chest pain) in adult patients.

Q: What types of other blood pressure medications interact with Adalat GITS?

A: The metabolism of nifedipine can be affected by other medicines, including certain beta-blockers, ACE inhibitors, and diuretics used to treat high blood pressure. These interactions are related to how the body processes the medicine, and monitoring by a healthcare professional is generally advised.

Q: How often do headaches occur when starting treatment with Adalat GITS?

A: Headache is listed in official documents as a common side effect of nifedipine, meaning it may affect up to 1 in 10 people. Regulatory labels do not provide a specific frequency rate for when the medicine is first started versus ongoing use.

Q: Can Adalat GITS cause vision changes or blurred vision?

A: Blurred vision is listed in official drug information as a possible side effect of nifedipine. Blurred vision is recognized as a potential effect within the medicine’s safety profile.

Q: Should I avoid alcohol entirely while taking Adalat GITS?

A: Consumption of alcohol may increase the effects of the medicine, potentially leading to an excessive drop in blood pressure or increased dizziness due to its blood vessel-widening action. Regulatory guidance suggests reviewing all consumption with a healthcare professional.

Q: Can certain over-the-counter pain relievers interact with Adalat GITS?

A: The official label mentions that nifedipine may interact with certain non-prescription pain relievers, such as aspirin. Official guidance emphasizes the importance of reviewing all medicines, including over-the-counter products and supplements.

Q: Is Adalat GITS generally considered appropriate for use by elderly patients?

A: The medicine is established for use in older adult populations, according to regulatory guidance. However, official information states that geriatric patients may require careful monitoring because they are more likely to have age-related issues affecting kidney, liver, or heart function.

Q: Are there specific medical conditions related to the stomach or intestines that are a concern with the GITS formulation?

A: Due to the unique nature of the controlled-release tablet, the use of Adalat GITS is prohibited in patients with oesophageal or gastrointestinal obstruction, narrowing, or a history of ileostomy.

Q: Does Adalat GITS pass into breast milk?

A: Studies indicate that the active ingredient, nifedipine, does pass into breast milk in small amounts. Official regulatory guidance includes the constraint that its use is generally not recommended while breastfeeding.

Q: How long does it typically take for Adalat GITS to begin lowering blood pressure?

A: The GITS formulation is designed for a gradual release, which results in a slow and sustained effect. Regulatory documents indicate that the plasma concentration builds up gradually and is then sustained at a near-constant level over the 24-hour dosing interval.

Q: Is Adalat GITS intended to be a long-term treatment or short-term therapy?

A: The medicine is indicated for the long-term management of chronic conditions, specifically essential hypertension and chronic stable angina. Typical use involves an ongoing maintenance dose regimen.

Q: Are there clinical studies comparing the effectiveness of the GITS formulation to other long-acting nifedipine products?

A: Yes, clinical studies have compared the efficacy and safety profiles of the GITS formulation to other long-acting nifedipine products. These studies often focus on differences in blood pressure control and the rates of specific side effects.

Q: Does the GITS system work differently depending on whether I take it with food or on an empty stomach?

A: According to the formulation's design, the GITS tablet releases nifedipine independently of whether it is taken with food or on an empty stomach. The effect of the tablet is intended to remain consistent regardless of mealtime.

Q: Can taking Adalat GITS affect a person's ability to drive or operate machinery?

A: Commonly reported side effects include dizziness, light-headedness, and tiredness. The presence of these effects necessitates caution regarding driving or operating complex machinery.

Q: Can Adalat GITS be used by people who have a history of allergies to other medicines?

A: The medicine is strictly contraindicated in patients with a known hypersensitivity to nifedipine or any other medicine belonging to the dihydropyridine class of calcium channel blockers. General allergy history is part of the overall assessment before use.

Q: Can Adalat GITS cause changes in weight (gain or loss)?

A: Official safety documents indicate that unusual weight gain or loss should be monitored. This is because weight changes may be linked to fluid retention (peripheral edema), which is a common side effect of this medication.

Q: Are there special considerations for taking Adalat GITS if a person has kidney problems?

A: Caution and careful monitoring may be required for patients with pre-existing kidney problems. Official information notes that older patients are more likely to have age-related kidney issues.

Q: Can taking Adalat GITS affect blood sugar levels in people with diabetes?

A: The medicine can interact with certain diabetes medications, such as metformin, which necessitates careful monitoring. Regulatory guidance notes that blood sugar monitoring may be performed more often for patients with diabetes when taking nifedipine.

Q: What non-prescription medicines or supplements should be checked for interactions with Adalat GITS?

A: Interactions are known with certain herbal supplements, such as St. John’s Wort, and some common over-the-counter pain relievers, like aspirin. Official information emphasizes reviewing all prescription and non-prescription products for potential interactions.

Q: Are there any reported cases of a bezoar (blockage) forming with the GITS tablet?

A: Post-marketing reports have documented rare cases of gastrointestinal obstruction, including the need for bezoar removal, in association with the GITS tablet formulation. This is related to the inert, controlled-release outer shell.

Q: Can Adalat GITS affect the gums or cause swelling in the mouth?

A: Regulatory literature includes reports of gingival hyperplasia, which is swelling or overgrowth of the gums, in some patients treated with nifedipine. This is a condition related to calcium channel modulation.

Q: Are there any known long-term side effects associated with the use of Adalat GITS?

A: While generally well-tolerated over long periods, rare but chronic side effects have been documented in regulatory literature. These include transient or mild elevations in liver enzyme levels, which often resolve even with continued use.

Q: What is the general expectation if a dose of Adalat GITS is missed?

A: Missing a dose interrupts the medicine's continuous 24-hour release mechanism, which is designed to maintain steady drug levels. The general expectation is that this may lead to a temporary loss of the medicine's intended effect on blood pressure or angina control.

Q: Can Adalat GITS interact with anti-seizure medicines?

A: Nifedipine can interact with certain anti-seizure medicines (anticonvulsants) that affect the CYP3A4 enzyme system. This type of interaction can alter the concentration of nifedipine in the body, which requires monitoring.

Q: Is Adalat GITS the same as Adalat CC?

A: Adalat GITS and Adalat CC are two distinct extended-release formulations of nifedipine. They utilize different delivery technologies and have distinctions in their official administration guidance, such as whether they should be taken with or without food.

How to Store and Dispose of Adalat GITS

Adalat GITS (Nifedipine) tablets must be stored according to strict regulatory requirements to maintain their pharmaceutical stability.

---

Official Storage Conditions

Requirement	Specific Condition
Temperature Limit	Do not store above 30 C.
Protection	Store in a cool, dry place, protected from strong light.
Packaging	Keep the tablets in the original container and blister pack until the time of use.
Child Safety	Must be stored out of the reach and sight of children.

Proper storage is necessary to ensure the labeled shelf-life of three to four years is maintained.

---

Disposal Instructions

Unused or expired Adalat GITS and any associated waste material must be disposed of in accordance with local regulations for pharmaceutical waste. The medicine must not be thrown away via wastewater or standard household waste.